Erschienen in:
12.08.2022 | Research Letter
Intravenous cyclophosphamide as an alternative to the oral cyclophosphamide modified Ponticelli regimen for high-risk PLA2R-positive membranous nephropathy
verfasst von:
Gabriel Ștefan, Adrian Zugravu, Simona Stancu
Erschienen in:
Journal of Nephrology
|
Ausgabe 2/2023
Einloggen, um Zugang zu erhalten
Excerpt
The mainstay of treatment for high-risk primary membranous nephropathy (MN) is the cyclic steroid-oral cyclophosphamide (cs-oral CYC) regimen (modified Ponticelli regimen) [
1]. However, there has been increasing awareness of serious treatment-related toxicity [
2,
3]. Intravenous CYC (iv-CYC) offers the potential benefit of lower cumulative dose and a lower rate of adverse events [
4,
5]. …